#

Vazhnoe

: 623
Photo: jackpress / Shutterstock
News·
Cloud AI provider Nebius reported its best quarter ever. Its stock soared
Norways sovereign wealth fund has disclosed its stake in Elon Musks aerospace company SpaceX / Photo: ChicagoPhotographer / Shutterstock
News·
The world's largest sovereign wealth fund has invested $1.2 billion in SpaceX shares
Arkady Volozh of data center provider Nebius will release financial results this week / Photo: X/Nebius
News·
U.S. Inflation, Eurozone GDP, and Nebius Earnings: What Investors Need to Know This Week
This year, Nebius shares have risen 130% in price, but most analysts still recommend buying them / Photo: Piotr Swat / Shutterstock.com
News·
An investor from "Short Game" bet against Nebius ahead of its quarterly report
Latigo was created by venture capital firm Westlake BioPartners and staffed with former neuroscience employees from Amgen / Photo: THICHA SATAPITANON / Shutterstock
Small Caps·
+1
·
Latigo IPO: Non-opioid painkiller maker debuts on the Nasdaq
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
News·
BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
Electricity providers are benefiting from growing demand from data centers and the industrial sector. Photo: entergy.com
Review·
Where to Invest $10,000: Betting on Chip-Free AI and Protecting Against Volatility. August Ideas
SpaceX investors continue to pay for a compelling narrative rather than proven growth in the business, cautions the CFRA analyst / Photo: Frederic Legrand - COMEO / Shutterstock.com
News·
'A game of hot potato': An early SpaceX pessimist speaks with Oninvest on key risks
Photo: Seacalm/Shutterstock
News·
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available
Attovia is developing drugs using a licensed technology platform and patents, with one drug having completed dosing in a phase I trial and another expected to start trials in early 2027 / Photo: Unsplash / Mathurin Napoli / matnapo
Small Caps·
+1
·
Attovia IPO: Goldman-backed biotech debuts on the Nasdaq
The end of the first lock-up period for SpaceX investors could prove to be even more significant in terms of its impact on the stock price than the company’s first financial report. Photo: SpaceX / Unsplash.com
Review·
SpaceX at $100? In the coming days, the market will put Musk's strategy to the test
Elon Musks SpaceX will release its first quarterly report this week following its IPO / Photo: X/SpaceX
News·
SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week
Load more